In addition, in preclinical breast cancer models, GLUT1 inhibitors have shown synergistic effects with current cancer therapies, including radiation treatment, cisplatin, paclitaxel, and adriamycin [129,130,131]. The gene discussed is SLC2A1; the disease is breast carcinoma.